Patient Name : Mr.

DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM

Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:03PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF HAEMATOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA
HAEMOGLOBIN 13 g/dL 13-17 Spectrophotometer
PCV 39.60 % 40-50 Electronic pulse &
Calculation
RBC COUNT 4.51 Million/cu.mm 4.5-5.5 Electrical Impedence
MCV 88 fL 83-101 Calculated
MCH 28.8 pg 27-32 Calculated
MCHC 32.8 g/dL 31.5-34.5 Calculated
R.D.W 14.6 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 5,400 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 56.4 % 40-80 Electrical Impedance
LYMPHOCYTES 33.1 % 20-40 Electrical Impedance
EOSINOPHILS 5.3 % 1-6 Electrical Impedance
MONOCYTES 4.6 % 2-10 Electrical Impedance
BASOPHILS 0.6 % <1-2 Electrical Impedance
CORRECTED TLC 5,400 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 3045.6 Cells/cu.mm 2000-7000 Calculated
LYMPHOCYTES 1787.4 Cells/cu.mm 1000-3000 Calculated
EOSINOPHILS 286.2 Cells/cu.mm 20-500 Calculated
MONOCYTES 248.4 Cells/cu.mm 200-1000 Calculated
BASOPHILS 32.4 Cells/cu.mm 0-100 Calculated
Neutrophil lymphocyte ratio (NLR) 1.7 0.78- 3.53 Calculated
PLATELET COUNT 152000 cells/cu.mm 150000-410000 Electrical impedence

Page 1 of 22

SIN No:HA07439671
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:08PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF HAEMATOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

ERYTHROCYTE SEDIMENTATION 16 mm at the 0-15 Modified Westergren
RATE (ESR) , WHOLE BLOOD EDTA end of 1 hour

Page 2 of 22

SIN No:HA07439671
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:31PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

GLUCOSE, FASTING , NAF PLASMA 98 mg/dL 70-100 GOD - POD

Comment:
As per American Diabetes Guidelines, 2023
Fasting Glucose Values in mg/dL Interpretation
70-100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
<70 mg/dL Hypoglycemia
Note:
1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of
> or = 200 mg/dL on at least 2 occasions.
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name Result Unit Bio. Ref. Interval Method

HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA
HBA1C, GLYCATED HEMOGLOBIN 5.8 % HPLC
ESTIMATED AVERAGE GLUCOSE 120 mg/dL Calculated
(eAG)
Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
Page 3 of 22

SIN No:BI21170402
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:31PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

FAIR TO GOOD CONTROL 7–8

UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is
advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may
not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 4 of 22

SIN No:BI21170402
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:31PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Page 5 of 22

SIN No:BI21170402
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 03:08PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

LIPID PROFILE , SERUM
TOTAL CHOLESTEROL 126 mg/dL <200 CHE/CHO/POD
TRIGLYCERIDES 149 mg/dL <150 Enzymatic
HDL CHOLESTEROL 43 mg/dL >40 CHE/CHO/POD
NON-HDL CHOLESTEROL 83 mg/dL <130 Calculated
LDL CHOLESTEROL 53.2 mg/dL <100 Calculated
VLDL CHOLESTEROL 29.8 mg/dL <30 Calculated
CHOL / HDL RATIO 2.93 0-4.97 Calculated
ATHEROGENIC INDEX (AIP) 0.18 <0.11 Calculated

Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Desirable Borderline High High Very High

TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240
TRIGLYCERIDES <150 150 - 199 200 - 499 ≥ 500
Optimal < 100
LDL 130 - 159 160 - 189 ≥ 190
Near Optimal 100-129
HDL ≥ 60
Optimal <130;
NON-HDL CHOLESTEROL 160-189 190-219 >220
Above Optimal 130-159

Measurements in the same patient can show physiological and analytical variations.
NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 6 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:51PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST (LFT) , SERUM
BILIRUBIN, TOTAL 1.00 mg/dL 0.20-1.20 Colorimetric
BILIRUBIN CONJUGATED (DIRECT) 0.22 mg/dL 0.0-0.3 Calculated
BILIRUBIN (INDIRECT) 0.78 mg/dL 0.0-1.1 Dual Wavelength
ALANINE AMINOTRANSFERASE 27 U/L 21-72 UV with P-5-P
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 19.0 U/L 17-59 UV with P-5-P
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 0.7 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 66.00 U/L 38-126 p-nitrophenyl
phosphate
PROTEIN, TOTAL 6.94 g/dL 6.3-8.2 Biuret
ALBUMIN 4.42 g/dL 3.5 - 5 Bromocresol Green
GLOBULIN 2.52 g/dL 2.0-3.5 Calculated
A/G RATIO 1.75 0.9-2.0 Calculated

Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of
bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:
1. Hepatocellular Injury:
*AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal
injuries. *ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for
hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with
ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This
ratio is also seen to be increased in NAFLD, Wilsons’s diseases, Cirrhosis, but the increase is usually not >2.
2. Cholestatic Pattern:
*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age
and sex. *Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
3. Synthetic function impairment:
*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.
Page 7 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:51PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Page 8 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:09PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM
CREATININE 0.69 mg/dL 0.72 – 1.18 Modified Jaffe, Kinetic
UREA 12.20 mg/dL 19-43 Urease
BLOOD UREA NITROGEN 5.7 mg/dL 8.0 - 23.0 Calculated
URIC ACID 5.43 mg/dL 3.5-8.5 Uricase
CALCIUM 9.11 mg/dL 8.4 - 10.2 Arsenazo-III
PHOSPHORUS, INORGANIC 3.85 mg/dL 2.5-4.5 PMA Phenol
SODIUM 136.66 mmol/L 135-145 Direct ISE
POTASSIUM 3.9 mmol/L 3.5-5.1 Direct ISE
CHLORIDE 101.44 mmol/L 98 - 107 Direct ISE
PROTEIN, TOTAL 6.94 g/dL 6.3-8.2 Biuret
ALBUMIN 4.42 g/dL 3.5 - 5 Bromocresol Green
GLOBULIN 2.52 g/dL 2.0-3.5 Calculated
A/G RATIO 1.75 0.9-2.0 Calculated

Page 9 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:51PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

CALCIUM , SERUM 9.11 mg/dL 8.4 - 10.2 Arsenazo-III

Page 10 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:09PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

C-REACTIVE PROTEIN CRP 0.15 mg/L <5 IMMUNO-
(QUANTITATIVE) , SERUM TURBIDIMETRY

Comment:

C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. Measuring changes in the
concentration of CRP provides useful diagnostic information about the level of acuity and severity of a disease. Unlike ESR, CRP
levels are not influenced by hematologic conditions such as anemia, polycythemia etc.

Increased levels are consistent with an acute inflammatory process. After onset of an acute phase response, the serum CRP
concentration rises rapidly (within 6-12 hours and peaks at 24-48 hours) and extensively.Concentrations above 100 mg/L are
associated with severe stimuli such as major trauma and severe infection (sepsis).

Page 11 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 01:51PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

IRON , SERUM 96.0 µg/dL 49-181 Ferene

Page 12 of 22

SIN No:BI21170400
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:16PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM
TRI-IODOTHYRONINE (T3, TOTAL) 1.08 ng/mL 0.7-2.04 CLIA
THYROXINE (T4, TOTAL) 7.65 µg/dL 5.48-14.28 CLIA
THYROID STIMULATING HORMONE 3.493 µIU/mL 0.34-5.60 CLIA
(TSH)

Comment:
Bio Ref Range for TSH in uIU/ml (As per
For pregnant females
American Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0
1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its
prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of
normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive
hormone. Only a very small fraction of circulating hormone is free and biologically active.
4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication &
circulating antibodies.
TSH T3 T4 FT4 Conditions
High Low Low Low Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement
High N N N
Therapy.
N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Low High High High Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
Page 13 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:16PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Pituitary Adenoma; TSHoma/Thyrotropinoma

High High High High

Page 14 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:16PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

VITAMIN D (25 - OH VITAMIN D) , 9.27 ng/mL CLIA
SERUM

Comment:
BIOLOGICAL REFERENCE RANGES
VITAMIN D STATUS VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY <10
INSUFFICIENCY 10 – 30
SUFFICIENCY 30 – 100
TOXICITY >100

The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is
the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency
can also cause osteomalacia, which frequently affects elderly patients.
Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of
which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as
well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.
Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D,
which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin
D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval
of greater than 30 ng/mL is a target value established by the Endocrine Society.
Decreased Levels:
Inadequate exposure to sunlight.
Dietary deficiency.
Vitamin D malabsorption.
Severe Hepatocellular disease.
Drugs like Anticonvulsants.
Nephrotic syndrome.
Increased levels:
Vitamin D intoxication.

Page 15 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 02:16PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

VITAMIN B12 , SERUM 181 pg/mL 180-914 CLIA

Comment:
Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss
of proprioception, poor coordination, and affective behavioral changes. A significant increase in RBC MCV may be an important
indicator of vitamin B12 deficiency.
Patients taking vitamin B12 supplementation may have misleading results. A normal serum concentration of B12 does not rule out
tissue deficiency of vitamin B12 . The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical
symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations
are normal.

Page 16 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 03:15PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY

Test Name Result Unit Bio. Ref. Interval Method

CARCINO EMBRYONIC ANTIGEN 1.51 ng/mL CLIA
(CEA) , SERUM

Comment:
REFERENCE GROUP REFERENCE RANGE IN ng/mL
NON-SMOKERS <5
SMOKERS <10

CEA is increased in 75% of patients with carcinoma of endodermal origin (colon, stomach, pancreas, lung); in about one third of
patients with small cell carcinoma of the lung and in about two thirds with non–small cell carcinoma of the lung. It is increased in
90% of all patients with solid tissue tumors, especially with metastases to the liver or lung. Increased concentrations are suggestive
but not diagnostic of cancer.
CEA levels are used for monitoring colorectal cancer and selected other cancers such as medullary thyroid carcinoma, cancers of
the rectum, lung, pancreas, stomach, and ovaries. After complete removal of colon cancer, CEA should fall to normal in 6–12
weeks. Failure to decline to normal concentrations postoperatively suggests incomplete resection.
Prognosis is related to serum concentration at time of diagnosis. CEA concentrations <5 ng/mL before therapy suggest localized
disease and a favorable prognosis, but a concentration >10 ng/mL suggests extensive disease and a poor prognosis.
CEA is not useful in screening the general population for undetected cancers.

Page 17 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 03:15PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

TOTAL PROSTATIC SPECIFIC 0.650 ng/mL 0-4 CLIA
ANTIGEN (tPSA) , SERUM

Page 18 of 22

SIN No:IM08053915
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 13/Aug/2024 10:05AM
UHID/MR No : APJ1.0028711297 Reported : 13/Aug/2024 01:24PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF IMMUNOLOGY

Test Name Result Unit Bio. Ref. Interval Method

CA 15.3 , SERUM 12.84 U/mL < 30 ELFA

Comment:

CA 15.3 test uses two monoclonal antibodies (115D8 and DF3) which react with a circulating CA 15.3, antigen expressed
in human breast cancer cell.
CA 15.3 test is used for the monitoring of therapy and disease progression for patients with diagnosed malignant tumors.
A decrease in the CA 15.3 concentration can indicate a positive response to therapy and therefore good prognosis. A
constant increase in CA 15.3 concentration often reflects evolution of the tumor and a poor response to therapy.
Results from this test should be interpreted as part of a complete clinical profile and in conjunction with other diagnostic
techniques.
CA 15.3 assay cannot be used as a screening test for cancer.

Page 19 of 22

SIN No:IM08054197
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 12/Aug/2024 12:30PM
UHID/MR No : APJ1.0028711297 Reported : 12/Aug/2024 03:15PM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF CLINICAL PATHOLOGY

APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

COMPLETE URINE EXAMINATION (CUE) , URINE
PHYSICAL EXAMINATION
COLOUR PALE STRAW PALE YELLOW Visual
TRANSPARENCY CLEAR CLEAR Physical measurement
pH 7.5 5-7.5 DOUBLE INDICATOR
SP. GRAVITY 1.010 1.002-1.030 Bromothymol Blue
BIOCHEMICAL EXAMINATION
URINE PROTEIN NEGATIVE NEGATIVE PROTEIN ERROR OF
INDICATOR
GLUCOSE NEGATIVE NEGATIVE GLUCOSE OXIDASE
URINE BILIRUBIN NEGATIVE NEGATIVE AZO COUPLING
REACTION
URINE KETONES (RANDOM) NEGATIVE NEGATIVE SODIUM NITRO
PRUSSIDE
UROBILINOGEN NORMAL NORMAL MODIFED EHRLICH
REACTION
NITRITE NEGATIVE NEGATIVE Diazotization
LEUCOCYTE ESTERASE NEGATIVE NEGATIVE LEUCOCYTE
ESTERASE
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY
PUS CELLS 2-4 /hpf 0-5 Microscopy
EPITHELIAL CELLS 4-6 /hpf <10 MICROSCOPY
RBC NIL /hpf 0-2 MICROSCOPY
CASTS NIL 0-2 Hyaline Cast MICROSCOPY
CRYSTALS ABSENT ABSENT MICROSCOPY

Comment:
All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked
and verified by manual methods.
Microscopy findings are reported as an average of 10 high power fields.

Page 20 of 22

SIN No:C03039702
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 13/Aug/2024 10:18AM
UHID/MR No : APJ1.0028711297 Reported : 13/Aug/2024 11:49AM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF SEROLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

HBsAg , SERUM 0.13 S/C UNITS ECLIA

Comment:

RESULTS IN S/C UNITS Conclusion from Testing Algorithm

< 0.90 NON-REACTIVE
0.90 - 1.00 INDETERMINATE
>1.00 REACTIVE

Interpretation:

• This is a screening assay which detects the first serological marker of Hepatitis B as early as 4-16 weeks after exposure.
• It persists during acute illness and usually disappears 12-20 weeks after onset of symptoms. Persistence of HBsAg for more than
6 months indicates development of carrier state or chronic liver disease
• A negative test result does not exclude with certainty a possible exposure to or an infection with the hepatitis B virus.
• It is recommended that a positive result of HBsAg must be be confirmed using a different enzyme immunoassay kit or by using a
confirmatory assay based on neutralisation with human anti hepatitis B surface antibody and/or HBV PCR
• Based upon clinical history it may become necessary to test for presence of other markers of hepatitis B virus infection.

Page 21 of 22

SIN No:SE02274149
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
Patient Name : Mr.DINESH KUMAR PANDEY Collected : 12/Aug/2024 10:07AM
Age/Gender : 61 Y 7 M 10 D /M Received : 13/Aug/2024 10:18AM
UHID/MR No : APJ1.0028711297 Reported : 13/Aug/2024 11:49AM
Visit ID : DPATOPV58217 Status : Final Report
Ref Doctor : RAUSHAN KUMAR PANDEY Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Danapur Bazar,Patna

DEPARTMENT OF SEROLOGY
APOLLO FULL BODY CHECKUP - ADVANCE

Test Name Result Unit Bio. Ref. Interval Method

ANTI HCV , SERUM 0.06 S/Co 0-0.99 ECLIA

Comment:
VALUE IN S/C UNITS RESULTS
<0.90 NON-REACTIVE
0.90 - 1.00 INDETERMINATE
> 1.00 REACTIVE

Interpretation:
• This is a Screening assay.HCV Antibodies are usually not detectable during the first 2 months following infection, and they are
usually detectable by the late convalescent stage (>6 months of onset) of infection.
• A positive result indicates the presence of Hepatitis C virus (HCV) – specific IgG antibodies due to past (resolved) or chronic
Hepatitis C. CDC recommendation on anti-HCV testing includes the use of method specific optimal signal-to-cut-off ratio in
interpretation & reporting results. For s/co ratio - between 1 to 6- further supplemental tests are suggested for confirmation, while
s/co ratio > or = 6 associated with 95% or more high probability of being true positive.
• Suggested supplemental test for confirmation are direct detection of HCV RNA by the reverse transcriptase-PCR (RT-PCR)
• An indeterminate result indicates that HCV-specific IgG antibodies may or may not be present.Indeterminate results should be
interpreted along with patient's risk factors for HCV infection and clinical findings. Individuals at risk for HCV infection with
indeterminate results should be retested with an HCV antibody confirmatory test in 1 to 2 months to determine the definitive HCV
antibody status.
• A non-reactive result does not exclude the possibility of exposure to or infection with HCV.Patients with auto-immune liver
diseases, renal disorders may show falsely reactive results.

*** End Of Report ***

Page 22 of 22

SIN No:SE02274149
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
.

Name : Mr. DINESH KUMAR PANDEY

Lab No. : IM08059242 Age : 61 Years
Ref By : DR RAUSHAN KUMAR Gender : Male
Collected : 13/8/2024 3:33:00PM Reported : 15/8/2024 3:37:53PM
A/c Status : P Report Status : Final

Test Report

Test Name Results Units Bio. Ref. Interval

CA 72.4 (TAG-72) GASTRIC CANCER MARKER, 1.82 U/mL <6.90

SERUM
(ECLIA)
Note
1. This test is not recommended to screen Gastric cancer in the general population.
2. Sensitivity of monitoring Gastric carcinoma improves by combining CA 72.4 with CEA and CA 19.9
assays.
3. False negative/positive results are observed in patients receiving mouse monoclonal antibodies for
diagnosis or therapy
4. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or
absence of malignant disease. The assay value should be used in conjunction with findings from
clinical evaluation and other diagnostic procedures.
5. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last
dose.

Clinical Use
· An aid in the management of Gastric cancer patients
· Monitor the course of disease and predict recurrence in patients with Gastric carcinoma
· Useful in detecting residual tumor

-------------------------------------------------------------
| DISEASE | PERCENTAGE |
| | POSITIVITY OF CA 72.4 |
|-------------------------------------|-----------------------|
| Gastro-intestinal carcinoma | 40 |
|-------------------------------------|-----------------------|
| Lung cancer | 36 |
|-------------------------------------|-----------------------|
| Ovarian cancer | 24 |
|-------------------------------------|-----------------------|
| Benign gastro-intestinal diseases | 6.7 |
|-------------------------------------|-----------------------|
| Healthy individuals | 3.5 |
-------------------------------------------------------------

Increased Levels
· Gastric carcinoma
· Ovarian carcinoma
· Benign diseases - Pancreatitis, Cirrhosis, Pulmonary disease, Rheumatic conditions, Ovarian cysts,
Benign breast disease, Benign gastro-intestinal disorders

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)
Page 1 of 2
.

Name : Mr. DINESH KUMAR PANDEY

Lab No. : IM08059242 Age : 61 Years
Ref By : DR RAUSHAN KUMAR Gender : Male
Collected : 13/8/2024 3:33:00PM Reported : 15/8/2024 3:37:53PM
A/c Status : P Report Status : Final

Test Report
-------------------------------End of report --------------------------------
*This test is performed at our Referral laboratory. Please refer to conditions of reporting.
This report is not valid for medico legal purposes.

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)
Page 2 of 2